Advertisement

Metabolic Syndrome

  • Susan L. Samson
    Affiliations
    Department of Medicine, Baylor College of Medicine, One Baylor Plaza, ABBR R615, Houston, TX 77030, USA
    Search for articles by this author
  • Alan J. Garber
    Correspondence
    Corresponding author. Department of Medicine, Baylor College of Medicine, One Baylor Plaza, BCM 620, Houston, TX 77030.
    Affiliations
    Department of Medicine, Baylor College of Medicine, One Baylor Plaza, BCM 620, Houston, TX 77030, USA

    Department of Molecular and Cellular Biology, Baylor College of Medicine, One Baylor Plaza, BCM 620, Houston, TX 77030, USA

    Department of Biochemistry and Molecular Biology, Baylor College of Medicine, One Baylor Plaza, BCM 620, Houston, TX 77030, USA
    Search for articles by this author

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Endocrinology and Metabolism Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Rossner S.
        Eskil Kylin (1885–1974).
        Obes Rev. 2009; 10: 362
        • Vague J.
        The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease.
        Am J Clin Nutr. 1956; 4: 20-34
        • Oda E.
        Metabolic syndrome: its history, mechanisms, and limitations.
        Acta Diabetol. 2012; 49: 89-95
        • Haller H.
        Epidemiology and associated risk factors of hyperlipoproteinemia.
        Z Gesamte Inn Med. 1977; 32 ([in German]): 124-128
        • Singer P.
        Diagnosis of primary hyperlipoproteinemias.
        Z Gesamte Inn Med. 1977; 32 ([in German]): 129-133
        • Phillips G.B.
        Sex hormones, risk factors and cardiovascular disease.
        Am J Med. 1978; 65: 7-11
        • Reaven G.M.
        Banting lecture 1988. Role of insulin resistance in human disease.
        Diabetes. 1988; 37: 1595-1607
      1. WHO obesity and overweight fact sheet no. 311. Available at: http://www.who.int/mediacentre/factsheets/fs311/en/. Accessed October 23, 2013.

        • Hossain P.
        • Kawar B.
        • El N.M.
        Obesity and diabetes in the developing world–a growing challenge.
        N Engl J Med. 2007; 356: 213-215
        • Alberti K.G.
        • Zimmet P.Z.
        Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.
        Diabet Med. 1998; 15: 539-553
        • Balkau B.
        • Charles M.A.
        Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR).
        Diabet Med. 1999; 16: 442-443
        • Einhorn D.
        • Reaven G.M.
        • Cobin R.H.
        • et al.
        American College of Endocrinology position statement on the insulin resistance syndrome.
        Endocr Pract. 2003; 9: 237-252
        • Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
        Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III).
        JAMA. 2001; 285: 2486-2497
      2. Available at: http://www.idf.org/webdata/docs/Metac_syndrome_def.pdf. Accessed October 23, 2013.

        • Grundy S.M.
        • Brewer Jr., H.B.
        • Cleeman J.I.
        • et al.
        Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition.
        Arterioscler Thromb Vasc Biol. 2004; 24: e13-e18
        • Alberti K.G.
        • Zimmet P.
        • Shaw J.
        Metabolic syndrome–a new world-wide definition. A Consensus Statement from the International Diabetes Federation.
        Diabet Med. 2006; 23: 469-480
        • Alberti K.G.
        • Eckel R.H.
        • Grundy S.M.
        • et al.
        Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity.
        Circulation. 2009; 120: 1640-1645
        • Marcovecchio M.L.
        • Chiarelli F.
        Metabolic syndrome in youth: chimera or useful concept?.
        Curr Diab Rep. 2013; 13: 56-62
        • Cook S.
        • Weitzman M.
        • Auinger P.
        • et al.
        Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988–1994.
        Arch Pediatr Adolesc Med. 2003; 157: 821-827
        • Zimmet P.
        • Alberti K.G.
        • Kaufman F.
        • et al.
        The metabolic syndrome in children and adolescents–an IDF consensus report.
        Pediatr Diabetes. 2007; 8: 299-306
        • Beltran-Sanchez H.
        • Harhay M.O.
        • Harhay M.M.
        • et al.
        Prevalence and trends of metabolic syndrome in the adult US population, 1999–2010.
        J Am Coll Cardiol. 2013; 62: 697-703
        • Gao W.
        Does the constellation of risk factors with and without abdominal adiposity associate with different cardiovascular mortality risk?.
        Int J Obes (Lond). 2008; 32: 757-762
        • Pandit K.
        • Goswami S.
        • Ghosh S.
        • et al.
        Metabolic syndrome in South Asians.
        Indian J Endocrinol Metab. 2012; 16: 44-55
        • Mabry R.M.
        • Reeves M.M.
        • Eakin E.G.
        • et al.
        Gender differences in prevalence of the metabolic syndrome in Gulf Cooperation Council Countries: a systematic review.
        Diabet Med. 2010; 27: 593-597
        • Lee S.R.
        • Cha M.J.
        • Kang D.Y.
        • et al.
        Increased prevalence of metabolic syndrome among hypertensive population: ten years' trend of the Korean National Health and Nutrition Examination Survey.
        Int J Cardiol. 2013; 166: 633-639
        • Unno M.
        • Furusyo N.
        • Mukae H.
        • et al.
        The utility of visceral fat level by bioelectrical impedance analysis in the screening of metabolic syndrome–the results of the Kyushu and Okinawa Population Study (KOPS).
        J Atheroscler Thromb. 2012; 19: 462-470
        • Gu D.
        • Reynolds K.
        • Wu X.
        • et al.
        Prevalence of the metabolic syndrome and overweight among adults in China.
        Lancet. 2005; 365: 1398-1405
        • Wilson P.W.
        • D'Agostino R.B.
        • Parise H.
        • et al.
        Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus.
        Circulation. 2005; 112: 3066-3072
        • Scuteri A.
        • Najjar S.S.
        • Morrell C.H.
        • et al.
        The metabolic syndrome in older individuals: prevalence and prediction of cardiovascular events: the Cardiovascular Health Study.
        Diabetes Care. 2005; 28: 882-887
        • Sattar N.
        • McConnachie A.
        • Shaper A.G.
        • et al.
        Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies.
        Lancet. 2008; 371: 1927-1935
        • Liu M.
        • Wang J.
        • Jiang B.
        • et al.
        Increasing prevalence of metabolic syndrome in a Chinese elderly population: 2001–2010.
        PLoS One. 2013; 8: e66233
        • Cook S.
        • Auinger P.
        • Li C.
        • et al.
        Metabolic syndrome rates in United States adolescents, from the National Health and Nutrition Examination Survey, 1999–2002.
        J Pediatr. 2008; 152: 165-170
        • Monzani A.
        • Rapa A.
        • Fuiano N.
        • et al.
        Metabolic syndrome is strictly associated with parental obesity beginning from childhood.
        Clin Endocrinol (Oxf). 2013; ([Epub ahead of print])
        • Randeva H.S.
        • Tan B.K.
        • Weickert M.O.
        • et al.
        Cardiometabolic aspects of the polycystic ovary syndrome.
        Endocr Rev. 2012; 33: 812-841
        • Apridonidze T.
        • Essah P.A.
        • Iuorno M.J.
        • et al.
        Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome.
        J Clin Endocrinol Metab. 2005; 90: 1929-1935
        • Glueck C.J.
        • Papanna R.
        • Wang P.
        • et al.
        Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome.
        Metabolism. 2003; 52: 908-915
        • Moran L.J.
        • Misso M.L.
        • Wild R.A.
        • et al.
        Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis.
        Hum Reprod Update. 2010; 16: 347-363
        • Carmina E.
        • Napoli N.
        • Longo R.A.
        • et al.
        Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS.
        Eur J Endocrinol. 2006; 154: 141-145
        • Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group
        Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).
        Hum Reprod. 2004; 19: 41-47
        • Gutierrez A.D.
        • Balasubramanyam A.
        Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management.
        Endocrine. 2012; 41: 1-10
        • Krishnan S.
        • Schouten J.T.
        • Atkinson B.
        • et al.
        Metabolic syndrome before and after initiation of antiretroviral therapy in treatment-naive HIV-infected individuals.
        J Acquir Immune Defic Syndr. 2012; 61: 381-389
        • Samaras K.
        • Wand H.
        • Law M.
        • et al.
        Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia.
        Diabetes Care. 2007; 30: 113-119
        • Alencastro P.R.
        • Wolff F.H.
        • Oliveira R.R.
        • et al.
        Metabolic syndrome and population attributable risk among HIV/AIDS patients: comparison between NCEP-ATPIII, IDF and AHA/NHLBI definitions.
        AIDS Res Ther. 2012; 9: 29
        • Freitas P.
        • Carvalho D.
        • Souto S.
        • et al.
        Impact of lipodystrophy on the prevalence and components of metabolic syndrome in HIV-infected patients.
        BMC Infect Dis. 2011; 11: 246
        • Verhelst J.
        • Mattsson A.F.
        • Luger A.
        • et al.
        Prevalence and characteristics of the metabolic syndrome in 2479 hypopituitary patients with adult-onset GH deficiency before GH replacement: a KIMS analysis.
        Eur J Endocrinol. 2011; 165: 881-889
        • Attanasio A.F.
        • Mo D.
        • Erfurth E.M.
        • et al.
        Prevalence of metabolic syndrome in adult hypopituitary growth hormone (GH)-deficient patients before and after GH replacement.
        J Clin Endocrinol Metab. 2010; 95: 74-81
        • Kahn R.
        Metabolic syndrome: is it a syndrome? Does it matter?.
        Circulation. 2007; 115: 1806-1810
        • Boronat M.
        • Saavedra P.
        • Varillas V.F.
        • et al.
        Differences in traditional and emerging cardiovascular risk factors of subjects discordantly classified by metabolic syndrome definitions of the International Diabetes Federation and the National Cholesterol Education Program.
        Nutr Metab Cardiovasc Dis. 2009; 19: 417-422
        • Eddy D.M.
        • Schlessinger L.
        • Heikes K.
        The metabolic syndrome and cardiovascular risk: implications for clinical practice.
        Int J Obes (Lond). 2008; 32: S5-S10
        • Fedorowski A.
        • Burri P.
        • Hulthen L.
        • et al.
        The metabolic syndrome and risk of myocardial infarction in familial hypertension (hypertension heredity in Malmö evaluation study).
        J Hypertens. 2009; 27: 109-117
        • Milionis H.J.
        • Kostapanos M.S.
        • Liberopoulos E.N.
        • et al.
        Different definitions of the metabolic syndrome and risk of first-ever acute ischaemic non-embolic stroke in elderly subjects.
        Int J Clin Pract. 2007; 61: 545-551
        • Nilsson P.M.
        • Engstrom G.
        • Hedblad B.
        The metabolic syndrome and incidence of cardiovascular disease in non-diabetic subjects–a population-based study comparing three different definitions.
        Diabet Med. 2007; 24: 464-472
        • Jeppesen J.
        • Hansen T.W.
        • Rasmussen S.
        • et al.
        Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: a population-based study.
        J Am Coll Cardiol. 2007; 49: 2112-2119
        • Wilson P.W.
        • Meigs J.B.
        Cardiometabolic risk: a Framingham perspective.
        Int J Obes (Lond). 2008; 32: S17-S20
        • Eberly L.E.
        • Prineas R.
        • Cohen J.D.
        • et al.
        Metabolic syndrome: risk factor distribution and 18-year mortality in the multiple risk factor intervention trial.
        Diabetes Care. 2006; 29: 123-130
        • Cull C.A.
        • Jensen C.C.
        • Retnakaran R.
        • et al.
        Impact of the metabolic syndrome on macrovascular and microvascular outcomes in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study 78.
        Circulation. 2007; 116: 2119-2126
        • Bruno G.
        • Merletti F.
        • Biggeri A.
        • et al.
        Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study.
        Diabetes Care. 2004; 27: 2689-2694
        • Kahn R.
        • Buse J.
        • Ferrannini E.
        • et al.
        The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.
        Diabetologia. 2005; 48: 1684-1699
        • Laakso M.
        Hyperglycemia and cardiovascular disease in type 2 diabetes.
        Diabetes. 1999; 48: 937-942
        • Ford E.S.
        • Schulze M.B.
        • Pischon T.
        • et al.
        Metabolic syndrome and risk of incident diabetes: findings from the European Prospective Investigation into Cancer and Nutrition-Potsdam Study.
        Cardiovasc Diabetol. 2008; 7: 35
        • Ford E.S.
        • Li C.
        • Sattar N.
        Metabolic syndrome and incident diabetes: current state of the evidence.
        Diabetes Care. 2008; 31: 1898-1904
        • Sattar N.
        • Gaw A.
        • Scherbakova O.
        • et al.
        Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study.
        Circulation. 2003; 108: 414-419
        • Wannamethee S.G.
        • Shaper A.G.
        • Lennon L.
        • et al.
        Metabolic syndrome vs Framingham risk score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus.
        Arch Intern Med. 2005; 165: 2644-2650
        • Cameron A.J.
        • Magliano D.J.
        • Zimmet P.Z.
        • et al.
        The metabolic syndrome as a tool for predicting future diabetes: the AusDiab study.
        J Intern Med. 2008; 264: 177-186
        • Krawczyk M.
        • Bonfrate L.
        • Portincasa P.
        Nonalcoholic fatty liver disease.
        Best Pract Res Clin Gastroenterol. 2010; 24: 695-708
        • Starley B.Q.
        • Calcagno C.J.
        • Harrison S.A.
        Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection.
        Hepatology. 2010; 51: 1820-1832
        • Smits M.M.
        • Ioannou G.N.
        • Boyko E.J.
        • et al.
        Non-alcoholic fatty liver disease as an independent manifestation of the metabolic syndrome: results of a US national survey in three ethnic groups.
        J Gastroenterol Hepatol. 2013; 28: 664-670
        • Castro-Martinez M.G.
        • Banderas-Lares D.Z.
        • Ramirez-Martinez J.C.
        • et al.
        Prevalence of nonalcoholic fatty liver disease in subjects with metabolic syndrome.
        Cir Cir. 2012; 80: 128-133
        • Caballeria L.
        • Pera G.
        • Rodriguez L.
        • et al.
        Metabolic syndrome and nonalcoholic fatty liver disease in a Spanish population: influence of the diagnostic criteria used.
        Eur J Gastroenterol Hepatol. 2012; 24: 1007-1011
        • Calle E.E.
        • Rodriguez C.
        • Walker-Thurmond K.
        • et al.
        Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.
        N Engl J Med. 2003; 348: 1625-1638
        • Gilbert C.A.
        • Slingerland J.M.
        Cytokines, obesity, and cancer: new insights on mechanisms linking obesity to cancer risk and progression.
        Annu Rev Med. 2013; 64: 45-57
        • Giovannucci E.
        • Harlan D.M.
        • Archer M.C.
        • et al.
        Diabetes and cancer: a consensus report.
        CA Cancer J Clin. 2010; 60: 207-221
        • Oda E.
        The metabolic syndrome as a concept of adipose tissue disease.
        Hypertens Res. 2008; 31: 1283-1291
        • Bremer A.A.
        • Jialal I.
        Adipose tissue dysfunction in nascent metabolic syndrome.
        J Obes. 2013; 2013: 393192
        • Fox C.S.
        • Massaro J.M.
        • Hoffmann U.
        • et al.
        Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study.
        Circulation. 2007; 116: 39-48
        • Neeland I.J.
        • Ayers C.R.
        • Rohatgi A.K.
        • et al.
        Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults.
        Obesity (Silver Spring). 2012; 21: E439-E447
        • Bergman R.N.
        • Kim S.P.
        • Catalano K.J.
        • et al.
        Why visceral fat is bad: mechanisms of the metabolic syndrome.
        Obesity (Silver Spring). 2006; 14: 16S-19S
        • Bergman R.N.
        • Kim S.P.
        • Hsu I.R.
        • et al.
        Abdominal obesity: role in the pathophysiology of metabolic disease and cardiovascular risk.
        Am J Med. 2007; 120: S3-S8
        • Klop B.
        • Elte J.W.
        • Cabezas M.C.
        Dyslipidemia in obesity: mechanisms and potential targets.
        Nutrients. 2013; 5: 1218-1240
        • Nikolic D.
        • Katsiki N.
        • Montalto G.
        • et al.
        Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches.
        Nutrients. 2013; 5: 928-948
        • Subramanian S.
        • Chait A.
        Hypertriglyceridemia secondary to obesity and diabetes.
        Biochim Biophys Acta. 2012; 1821: 819-825
        • Gupta A.
        • Gupta V.
        Metabolic syndrome: what are the risks for humans?.
        Biosci Trends. 2010; 4: 204-212
        • Reaven G.M.
        Relationships among insulin resistance, type 2 diabetes, essential hypertension, and cardiovascular disease: similarities and differences.
        J Clin Hypertens (Greenwich ). 2011; 13: 238-243
        • Andreassi M.G.
        Metabolic syndrome, diabetes and atherosclerosis: influence of gene-environment interaction.
        Mutat Res. 2009; 667: 35-43
        • Landsberg L.
        • Aronne L.J.
        • Beilin L.J.
        • et al.
        Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment–a position paper of the Obesity Society and the American Society of Hypertension.
        Obesity (Silver Spring). 2013; 21: 8-24
        • Kershaw E.E.
        • Flier J.S.
        Adipose tissue as an endocrine organ.
        J Clin Endocrinol Metab. 2004; 89: 2548-2556
        • Matsuzawa Y.
        • Funahashi T.
        • Nakamura T.
        The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism.
        J Atheroscler Thromb. 2011; 18: 629-639
        • West M.
        Dead adipocytes and metabolic dysfunction: recent progress.
        Curr Opin Endocrinol Diabetes Obes. 2009; 16: 178-182
        • Cinti S.
        • Mitchell G.
        • Barbatelli G.
        • et al.
        Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans.
        J Lipid Res. 2005; 46: 2347-2355
        • Semenkovich C.F.
        Insulin resistance and atherosclerosis.
        J Clin Invest. 2006; 116: 1813-1822
        • Lusis A.J.
        • Attie A.D.
        • Reue K.
        Metabolic syndrome: from epidemiology to systems biology.
        Nat Rev Genet. 2008; 9: 819-830
        • Phillips C.M.
        Metabolically healthy obesity: definitions, determinants and clinical implications.
        Rev Endocr Metab Disord. 2013; 14: 219-227
        • O'Connell J.
        • Lynch L.
        • Cawood T.J.
        • et al.
        The relationship of omental and subcutaneous adipocyte size to metabolic disease in severe obesity.
        PLoS One. 2010; 5: e9997
        • O'Connell J.
        • Lynch L.
        • Hogan A.
        • et al.
        Preadipocyte factor-1 is associated with metabolic profile in severe obesity.
        J Clin Endocrinol Metab. 2011; 96: E680-E684
        • Povel C.M.
        • Boer J.M.
        • Reiling E.
        • et al.
        Genetic variants and the metabolic syndrome: a systematic review.
        Obes Rev. 2011; 12: 952-967
        • Jin T.
        The WNT signalling pathway and diabetes mellitus.
        Diabetologia. 2008; 51: 1771-1780
        • Ingelsson E.
        • Langenberg C.
        • Hivert M.F.
        • et al.
        Detailed physiologic characterization reveals diverse mechanisms for novel genetic loci regulating glucose and insulin metabolism in humans.
        Diabetes. 2010; 59: 1266-1275
        • Lyssenko V.
        • Lupi R.
        • Marchetti P.
        • et al.
        Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes.
        J Clin Invest. 2007; 117: 2155-2163
        • Florez J.C.
        • Jablonski K.A.
        • Bayley N.
        • et al.
        TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program.
        N Engl J Med. 2006; 355: 241-250
        • Phillips C.M.
        • Goumidi L.
        • Bertrais S.
        • et al.
        Dietary saturated fat, gender and genetic variation at the TCF7L2 locus predict the development of metabolic syndrome.
        J Nutr Biochem. 2012; 23: 239-244
        • Warodomwichit D.
        • Arnett D.K.
        • Kabagambe E.K.
        • et al.
        Polyunsaturated fatty acids modulate the effect of TCF7L2 gene variants on postprandial lipemia.
        J Nutr. 2009; 139: 439-446
        • Loos R.J.
        • Rankinen T.
        Gene-diet interactions on body weight changes.
        J Am Diet Assoc. 2005; 105: S29-S34
        • Loos R.J.
        • Lindgren C.M.
        • Li S.
        • et al.
        Common variants near MC4R are associated with fat mass, weight and risk of obesity.
        Nat Genet. 2008; 40: 768-775
        • Loos R.J.
        • Bouchard C.
        FTO: the first gene contributing to common forms of human obesity.
        Obes Rev. 2008; 9: 246-250
        • Frayling T.M.
        • Timpson N.J.
        • Weedon M.N.
        • et al.
        A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity.
        Science. 2007; 316: 889-894
        • Scuteri A.
        • Sanna S.
        • Chen W.M.
        • et al.
        Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits.
        PLoS Genet. 2007; 3: e115
        • Kooner J.S.
        • Chambers J.C.
        • Aguilar-Salinas C.A.
        • et al.
        Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides.
        Nat Genet. 2008; 40: 149-151
        • Grundy S.M.
        • Hansen B.
        • Smith Jr., S.C.
        • et al.
        Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management.
        Arterioscler Thromb Vasc Biol. 2004; 24: e19-e24
        • Yamaoka K.
        • Tango T.
        Effects of lifestyle modification on metabolic syndrome: a systematic review and meta-analysis.
        BMC Med. 2012; 10: 138
        • Orchard T.J.
        • Temprosa M.
        • Barrett-Connor E.
        • et al.
        Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study.
        Diabet Med. 2013; 30: 46-55
        • Kramer M.K.
        • Kriska A.M.
        • Venditti E.M.
        • et al.
        Translating the Diabetes Prevention Program: a comprehensive model for prevention training and program delivery.
        Am J Prev Med. 2009; 37: 505-511
        • Perreault L.
        • Pan Q.
        • Mather K.J.
        • et al.
        Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study.
        Lancet. 2012; 379: 2243-2251
        • Potenza M.V.
        • Mechanick J.I.
        The metabolic syndrome: definition, global impact, and pathophysiology.
        Nutr Clin Pract. 2009; 24: 560-577
        • Ridker P.M.
        • Pradhan A.
        • MacFadyen J.G.
        • et al.
        Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial.
        Lancet. 2012; 380: 565-571
        • Gotto Jr., A.M.
        • Moon J.E.
        Pharmacotherapies for lipid modification: beyond the statins.
        Nat Rev Cardiol. 2013; 10: 560-570
        • Boekholdt S.M.
        • Arsenault B.J.
        • Hovingh G.K.
        • et al.
        Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis.
        Circulation. 2013; 128: 1504-1512
      3. Clofibrate and niacin in coronary heart disease.
        JAMA. 1975; 231: 360-381
        • AIM-HIGH Investigators
        The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial.
        Am Heart J. 2011; 161: 538-543
        • Guyton J.R.
        • Slee A.E.
        • Anderson T.
        • et al.
        Relationship of lipoproteins to cardiovascular events in the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes (AIM-HIGH) Trial.
        J Am Coll Cardiol. 2013; ([Epub ahead of print])
        • HPS2-THRIVE Collaborative Group
        HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.
        Eur Heart J. 2013; 34: 1279-1291
        • Ginsberg H.N.
        • Bonds D.E.
        • Lovato L.C.
        • et al.
        Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
        Am J Cardiol. 2007; 99: 56i-67i
        • Ginsberg H.N.
        • Elam M.B.
        • Lovato L.C.
        • et al.
        Effects of combination lipid therapy in type 2 diabetes mellitus.
        N Engl J Med. 2010; 362: 1563-1574
        • Rubins H.B.
        • Robins S.J.
        • Collins D.
        • et al.
        Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
        N Engl J Med. 1999; 341: 410-418
        • Chobanian A.V.
        • Bakris G.L.
        • Black H.R.
        • et al.
        The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.
        JAMA. 2003; 289: 2560-2572
        • Knowler W.C.
        • Fowler S.E.
        • Hamman R.F.
        • et al.
        10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
        Lancet. 2009; 374: 1677-1686
        • Knowler W.C.
        • Barrett-Connor E.
        • Fowler S.E.
        • et al.
        Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
        N Engl J Med. 2002; 346: 393-403
        • Kahn R.
        • Buse J.
        • Ferrannini E.
        • et al.
        The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.
        Diabetes Care. 2005; 28: 2289-2304
        • Haffner S.M.
        The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease.
        Am J Cardiol. 2006; 97: 3A-11A
        • Simmons R.K.
        • Alberti K.G.
        • Gale E.A.
        • et al.
        The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation.
        Diabetologia. 2010; 53: 600-605
        • Kohli P.
        • Greenland P.
        Role of the metabolic syndrome in risk assessment for coronary heart disease.
        JAMA. 2006; 295: 819-821